Aug. 09, 2022 Kidney cancer innovations and collaborations Mayo Clinic kidney cancer experts discuss the multispecialty integrated approach they take to kidney cancer care. At Mayo Clinic Comprehensive Cancer Center, renal cancer experts draw on the best surgical, imaging, technical and pathology practices supported by care providers with specific kidney cancer expertise. Aug. 09, 2022 Testicular cancer advancements and innovations Mayo Clinic testicular cancer experts explain the methods they are using to work toward their goal of 100% cure for patients with testicular cancer. Advanced diagnosis and screening practices, collaboration in multidisciplinary teams, excellent therapy options and clinical trials help Mayo Clinic Comprehensive Cancer Center lead in innovation. Aug. 09, 2022 Bladder cancer discoveries implemented in multidisciplinary teams Bladder cancer experts at Mayo Clinic Comprehensive Cancer Center work in multidisciplinary teams to stay at the forefront of medical research and discoveries. Innovations in diagnostics, drug development, genomics, immunotherapy, surgery and imaging allow Mayo Clinic physicians the best options in treating bladder cancer. Aug. 09, 2022 Prostate cancer innovations move the field forward Prostate cancer experts at Mayo Clinic Comprehensive Cancer Center work in an integrated genitourinary practice, which allows them the size and scope they need to drive this rapidly moving field forward. Dec. 07, 2021 Treatment options for pelvic organ prolapse A Mayo Clinic urogynecologist discusses the latest treatment options for pelvic organ prolapse. Oct. 28, 2020 Current therapies for patients with overactive bladder Overactive bladder and its symptoms can be discouraging and debilitating for patients. Making use of the most current therapies and implementing them in a prescribed sequence, starting with the most conservative measures, is the key to managing the problem. Oct. 14, 2019 Newly discovered autoimmune disease associated with testicular cancer Sean J. Pittock, M.D., an autoimmune neurologist at Mayo Clinic, discusses a newly discovered autoimmune disease that appears to affect men with testicular cancer. Feb. 28, 2017 A multidisciplinary approach to genitourinary cancers Mayo Clinic specialists describe considerations and advancements in surgical techniques used in the treatment of testicular cancer, bladder cancer and kidney cancer. April 09, 2015 Surgical treatment options for people with prostate cancer Igor Frank, M.D., discusses surgical treatment options for people with prostate cancer. Oct. 31, 2014 Bladder cancer treatment options R. Jeffrey Karnes, M.D., consultant and associate professor, Mayo Clinic, discusses treatment options for bladder cancer. The ailment can be subdivided into subcategories, and the treatments dramatically differ. Invasive treatments can include an ileal neobladder created from the patient's small intestine, which can provide the best quality of life. Oct. 08, 2014 Mayo Clinic scientists propose a breast cancer drug for bladder cancer patients Amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC), has shown that the presence of HER2 amplification is associated with particularly aggressive tumors. Oct. 08, 2014 Mayo Clinic expert says heart disease from unnecessarily treating "Low T" serious concern Low T — health risks of testosterone therapy —- Mayo Clinic. William F. Young Jr., M.D. Oct. 07, 2014 Minority disparities evident in prostate cancer survival rate, Mayo Clinic study shows A Mayo Clinic study reviewed data on more than 290,000 men with prostate cancer from the past 20 years and found that African-American men are at increased risk of poorer survival rate following prostate cancer treatment compared with other minority groups. Oct. 01, 2014 Less-radical procedures offer similar cancer control compared with surgery for kidney cancer patients Needle-guided tumor destruction procedures offer near-equivalent lengths of local cancer control compared with surgery for patients with small kidney cancer tumors, according to the results of a large study published in the journal European Urology. July 08, 2014 Mayo Clinic researchers help to shine new light on bladder cancer tumors Mayo Clinic researchers help to shine new light on bladder cancer tumors. June 30, 2014 Erectile dysfunction: Harbinger of heart disease? Charanjit S. Rihal, M.D., and Stephen L. Kopecky, M.D., discuss erectile dysfunction and its impact on cardiovascular prognosis and diagnosis. June 27, 2014 PROMOTE: Prostate Cancer Medically Optimized Genome Enhanced Therapy Study The Prostate Cancer Medically Optimized Genome Enhanced Therapy Study (PROMOTE) aims to individualize treatments for men with castration-resistant prostate cancer. June 26, 2014 Ultrafiltration for Heart Failure (HF) with cardiorenal syndrome: CARRESSing the kidneys or rubbing them the wrong way? Eddie L. Greene, M.D., Horng H. Chen, M.D., and Margaret M. Redfield, M.D., gathered to discuss the design, results and implications of the cardiorenal rescue study in acute decompensated heart failure (CARRESS). May 22, 2014 Choline C-11: Pulling back the curtain on prostate cancer Mayo Clinic has integrated production, imaging and pathology facilities to provide the benefit of Choline C 11 PET imaging to prostate cancer patients. March 03, 2014 Prostate cancer developments — Mayo Clinic Proceedings Manish Kohli, M.D., of Mayo Clinic, discusses his January 2010 Mayo Clinic Proceedings article on new developments in the medical management of prostate cancer. March 03, 2014 Predictors of ADT response in advanced prostate cancer Manish Kohli, M.D., associate professor of medical oncology at Mayo Clinic in Rochester, Minnesota, discusses his article appearing in the March 2012 issue of Mayo Clinic Proceedings. March 03, 2014 New developments in the medical management of prostate cancer Manish Kohli, M.D., of Mayo Clinic, discusses his January 2010 Mayo Clinic Proceedings article on new developments in the medical management of prostate cancer. March 03, 2014 Mayo Clinic study suggests routine prostate size evaluation not as effective in cancer screening If a man's PSA is quickly rising, he likely deserves a prostate biopsy to determine if he has prostate cancer. Assessment of change in prostate size should not influence the decision to biopsy. Dr. Rodney Breau discusses the study and its findings in this video. Feb. 21, 2014 Biopsy-based predictors of prostate cancer mortality: The Mayo Model Matthew K. Tollefson, M.D., provides patients and clinicians with a novel way to predict which cases of prostate cancer, the most commonly diagnosed malignancy in American men, will be aggressive and which ones can be safely monitored with watchful waiting. Oct. 25, 2012 16-year longitudinal changes in serum prostate-specific antigen (PSA) levels Jennifer St. Sauver, Ph.D., associate professor of epidemiology in the Department of Health Sciences Research at Mayo Clinic in Rochester, Minnesota, discusses her article appearing in the January 2012 issue of Mayo Clinic Proceedings. المتخصصون في المجالات الطبية Urology videos